Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Week in Review: Sanofi Acquires Kadmon, a US-China Pharma, for $1.9 Billion
Deals and Financings
Bio-Thera Solutions (SHA: 688177) out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz (see story). Sandoz will also have rights in most other countries not already assigned. In 2020, Bio-Thera filed BLAs for BAT1706 in these countries, plus
Huadong Medicine (SHZ: 000963) entered a co-development partnership with Insilico Medicine, a Hong Kong AI drug discovery company (see story). The two companies will work together to develop small-molecule therapeutics in oncology. Huadong will use its drug discovery and screening platform, while Insilico will contribute its end-to-end AI-driven drug discovery platform, including its small molecule generation platform, Chemistry42, to design and screen for potential first-in-class drug molecules with improved druggability. The teams plan to interfere with protein-protein interactions to hit undruggable targets that regulate tumor growth.
Brii Biosciences of Beijing committed an additional $100 million for global regulatory filings and commercialization of its SARS-CoV-2 combination therapy (see story). BRII-196/BRII-198 is a neutralizing monoclonal antibody combination therapy. In a Phase III trial, interim results showed a statistically significant reduction of 78% in hospitalization/death among high risk, non-hospitalized COVID-19 patients. The results showed efficacy in all variants of the disease. The company will also expand manufacturing and establish partnerships to deliver the therapy globally.
Chengdu Clover Biopharma received a manufacturing permit for its S-Trimer COVID-19 vaccine candidate at its Changxing facility (see story). Clover is currently testing the vaccine in a global pivotal Phase II/III trial as a combination of the SCB-2019 antigen and two adjuvants. Clover plans to submit for conditional approval of SCB-2019 in
Sinovac Biotech (NSDQ: SVA) reported that a third dose of its inactivated SARS-CoV-2 vaccine improved the protection of CoronaVac® by 60%, including protection from the Delta variant (see story). The third dose was administered six months after the second shot, when the efficacy of the vaccine was already in decline. CoronaVac® was approved by WHO under emergency rules. Sinovac said the study provides a "theoretical basis" for a third dose of the vaccine, implying more studies would be required before regulatory approval.
Trials and Approvals
JW Therapeutics (HK: 2126), a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in